Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression
about
Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stromaMammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantationThe efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.Everolimus - a new approach in the treatment of renal cell carcinomaLow concentration of rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice.Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-α activation and disruption of the p120-vascular endothelial cadherin interaction.Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo.Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cellsCD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivoClass 1A PI3K regulates vessel integrity during development and tumorigenesis.Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors.Pathogenesis of infantile haemangioma.Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeabilityRapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.Signalling pathways passing Src in pancreatic endocrine tumours: relevance for possible combined targeted therapies.Protein kinases and associated pathways in pluripotent state and lineage differentiation.Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma.Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.Akt promotes endocardial-mesenchyme transitionAntagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.Mammalian target of rapamycin complex 1 (mTORC1) may modulate the timing of anagen entry in mouse hair follicles.Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.
P2860
Q28732327-EA96B259-73B5-4712-9F4E-CEAB964BBDEDQ33849666-5FBD7DB7-773B-484C-A0C7-BBB4FF54DDE0Q33898020-1586F77E-ACD3-4869-BE02-E056AEF51E4BQ34001234-9925F0CD-FE39-4456-BD50-7EA6EFA91990Q34135475-736D7E3A-CE96-445C-919C-52E4AF78D053Q34417931-F06C9681-18DC-4FB0-90F9-708F09F6F59FQ34498996-4070DC90-ADCA-493B-8C1D-9835F0C839ECQ34654684-9E03D83D-D7E3-4F4A-8D75-BE55E6AB9B1FQ35177682-8C8227EB-B2E0-4B7A-B96E-CB9F9CE5580FQ35834072-F5CBC060-FF36-4F19-8F5F-F3CB8853501CQ36384673-21A49516-A95B-4067-8D7A-367B6B2C486DQ36392591-F3818D6F-DC08-4944-A47A-510C7B1BB592Q36755338-33D084E4-9A1C-4273-8570-FF129878D905Q36977876-676C870F-C991-4355-8BA4-DD731BF77D5FQ37001304-DDF3B4A7-4C8B-46E2-BC3E-49ADF7AABF73Q37307982-9777D5A6-7283-4C67-A7FA-137D49BC050BQ37374986-370D1013-5C21-4F2D-919A-0D1EA1FCDFA4Q37996268-53722AD8-AB13-46E0-B3D5-C8B9AE0B1BBBQ38226659-A0337622-38A8-4AF6-9FD6-9FDA3B67C2C8Q38233105-DDAD0DF5-4AE8-4804-BBB2-4EC4943F91A1Q39027928-CC4B6F87-A61E-4E07-8D65-FAB657E894FBQ39111280-8DEB2A91-5726-4300-A5F4-7ABAAAC9E278Q39583739-28EE9137-A347-4267-83E9-F0B658DAD596Q41874128-2D7BE69B-B7EC-4A25-965C-B3B102E8692DQ46024830-EF745364-33D1-4A51-82F1-AFEC8746B9CAQ46250769-B3F24B90-BDCE-47D8-AC7F-C50F0C6D3C75Q47099537-F8DF45A1-DC42-44A3-80BA-A7FE30F41026
P2860
Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Endothelial Akt signaling is r ...... ouse mammary tumor progression
@ast
Endothelial Akt signaling is r ...... ouse mammary tumor progression
@en
type
label
Endothelial Akt signaling is r ...... ouse mammary tumor progression
@ast
Endothelial Akt signaling is r ...... ouse mammary tumor progression
@en
prefLabel
Endothelial Akt signaling is r ...... ouse mammary tumor progression
@ast
Endothelial Akt signaling is r ...... ouse mammary tumor progression
@en
P2093
P2860
P1433
P1476
Endothelial Akt signaling is r ...... ouse mammary tumor progression
@en
P2093
Charlotte Kuperwasser
Godfred Eyiah-Mensah
Kenneth Walsh
Laura E Benjamin
Radoslaw Bieniek
Rebekah K O'Donnell
Sharon Shechter
Thuy L Phung
P2860
P304
P356
10.1158/0008-5472.CAN-06-3341
P407
P577
2007-06-01T00:00:00Z